Floatz logo

Lirafugratinib

FGFR2 Gene Activation

Elevar TherapeuticsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the FGFR2 Gene Activation cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Lirafugratinib is also rated in:

Other Solid Tumors, AdultDormant
BB
Indicative ·
64 / 100
View asset →
FGFR2 Gene Fusion/RearrangementDormant
BB
Indicative ·
64 / 100
View asset →
FGFR2 AmplificationDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →